Jefferies initiated coverage of MBX Biosciences with a Buy rating and $35 price target The firm sees a high probability of success for MBX-2109 in Phase II for parathyroid hormone. MBX has a strong scientific peptide platform to extend duration of therapy and improve efficacy for peptides in PTH and obesity, while the shares look inexpensive at current levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
Questions or Comments about the article? Write to editor@tipranks.com